基于病理学的流感与COVID-19相关肺曲霉病病例系列:证据在组织中
该单中心、描述性、回顾性病例系列纳入2009年9月至2021年6月ICU收治的PCR确诊流感/COVID-19呼吸衰竭成人患者,行尸检和/或支气管活检。依据ICU医学流感相关肺曲霉病及ECMM/ISHAM COVID-19相关肺曲霉病共识标准诊断可能/确诊病毒相关肺曲霉病(VAPA)。44例尸检验证队列中,确诊流感相关6例、COVID-19相关6例;8%(1/12)确诊为尸检漏诊,52%(11/21)为生前可能诊断的确认且接受抗真菌治疗。支气管肺泡灌洗液半乳甘露聚糖检测敏感性最高,真菌生长受阻为主要组织学模式,流感与COVID-19真菌性气管支气管炎组织学不可区分但流感支气管镜下更广泛。
要点
- 44例尸检验证队列中确诊流感相关肺曲霉病6例、COVID-19相关肺曲霉病6例。
- 确诊VAPA中8%(1/12)为尸检漏诊,52%(11/21)为生前可能诊断的确认且已接受抗真菌治疗。
- 支气管肺泡灌洗液半乳甘露聚糖检测对VAPA诊断敏感性最高。
- 真菌生长受阻是两种病毒感染中肺曲霉病的主要组织学模式。
- 真菌性气管支气管炎在流感(n=3)与COVID-19(n=3)组织学不可区分,但流感支气管镜下更广泛。
适用人群与场景
- 2009年9月至2021年6月期间ICU收治的PCR确诊流感或COVID-19呼吸衰竭成人患者,且行尸检和/或ICU期间支气管活检。
诊断标准与关键阈值
- 依据ICU医学流感相关肺曲霉病标准及欧洲医学真菌学联盟(ECMM)与国际人类与动物真菌学学会(ISHAM)COVID-19相关肺曲霉病共识标准诊断可能/确诊病毒相关肺曲霉病(VAPA)。
- 所有呼吸组织由两位经验丰富的病理学家独立审阅。
研究设计与关键结果
- 单中心、描述性、回顾性病例系列,44例尸检验证队列中确诊流感相关肺曲霉病6例、COVID-19相关肺曲霉病6例。
- 确诊VAPA中8%(n=1/12)为尸检漏诊,52%(n=11/21)为生前可能诊断的确认且接受抗真菌治疗。
- 支气管肺泡灌洗液半乳甘露聚糖检测对VAPA诊断敏感性最高。
- 两种病毒感染中真菌生长受阻为主要组织学模式;真菌性气管支气管炎在流感(n=3)与COVID-19(n=3)组织学不可区分,但流感支气管镜下更广泛。
证据类型、等级与局限
- 证据类型:单中心、描述性、回顾性病例系列。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为研究结果强调需要提高对VAPA的认识,重点在于支气管镜真菌学检查。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Invasive pulmonary aspergillosis has emerged as a frequent coinfection in severe coronavirus disease (COVID-19), similarly to influenza, yet the clinical invasiveness is more debated. Objectives: We investigated the invasive nature of pulmonary aspergillosis in histology specimens of influenza and COVID-19 ICU fatalities in a tertiary care center. Methods: In this monocentric, descriptive, retrospective case series, we included adult ICU patients with PCR-proven influenza/COVID-19 respiratory failure who underwent postmortem examination and/or tracheobronchial biopsy during ICU admission from September 2009 until June 2021. Diagnosis of probable/proven viral-associated pulmonary aspergillosis (VAPA) was made based on the Intensive Care Medicine influenza-associated pulmonary aspergillosis and the European Confederation of Medical Mycology (ECMM) and the International Society for Human and Animal Mycology (ISHAM) COVID-19-associated pulmonary aspergillosis consensus criteria. All respiratory tissues were independently reviewed by two experienced pathologists. Measurements and Main Results: In the 44 patients of the autopsy-verified cohort, 6 proven influenza-associated and 6 proven COVID-19-associated pulmonary aspergillosis diagnoses were identified. Fungal disease was identified as a missed diagnosis upon autopsy in 8% of proven cases (n = 1/12), yet it was most frequently found as confirmation of a probable antemortem diagnosis (n = 11/21, 52%) despite receiving antifungal treatment. Bronchoalveolar lavage galactomannan testing showed the highest sensitivity for VAPA diagnosis. Among both viral entities, an impeded fungal growth was the predominant histologic pattern of pulmonary aspergillosis. Fungal tracheobronchitis was histologically indistinguishable in influenza (n = 3) and COVID-19 (n = 3) cases, yet macroscopically more extensive at bronchoscopy in influenza setting. Conclusions: A proven invasive pulmonary aspergillosis diagnosis was found regularly and with a similar histological pattern in influenza and in COVID-19 ICU case fatalities. Our findings highlight an important need for VAPA awareness, with an emphasis on mycological bronchoscopic work-up.
参考来源
- Vanderbeke L, Jacobs C, Feys S, et al. A Pathology-based Case Series of Influenza- and COVID-19-associated Pulmonary Aspergillosis: The Proof Is in the Tissue. Am J Respir Crit Care Med. 2023. PMID: 37311243. doi:10.1164/rccm.202208-1570OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。